Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758041 | 0.90 | PTGDR2 (0.49) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1757823 | 0.90 | PTGDR2 (0.52) | PTGDR2MAPTF2RL3CYP1A2CYP3A4 | |
| SCHEMBL1758032 | 0.89 | MAPT (0.52) | PTGDR2MAPTF2RL3CYP1A2CYP3A4 | |
| SCHEMBL1757545 | 0.86 | KMT2A (0.47) | PTGDR2MAPTF2RL3ALDH1A1LMNA | |
| SCHEMBL1757699 | 0.80 | PTGDR2 (0.60) | PTGDR2MAPTF2RL3CYP1A2CYP3A4 | |
| SCHEMBL1757984 | 0.80 | PTGDR2 (0.55) | PTGDR2MAPTF2RL3CYP1A2CYP3A4 | |
| SCHEMBL1757971 | 0.78 | PTGDR2 (0.50) | PTGDR2MAPTKRASTACR1ALDH1A1 | |
| SCHEMBL1757886 | 0.78 | PTGDR2 (0.80) | PTGDR2MAPTCYP2C9 | |
| SCHEMBL1758015 | 0.76 | KDM4E (0.48) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL318734 | 0.76 | PTGDR2 (0.72) | PTGDR2MAPTCYP2C9PTGS1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885MAPT 4275/4885F2RL3 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.